Get the Stockscreener App
0.4373
2.45%
-0.011
After Hours:
.44
0.0027
+0.62%
Theriva Biologics Inc stock is traded at $0.4373, with a volume of 1.21M.
It is down -2.45% in the last 24 hours and up +5.30% over the past month.
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11. It has collaborations with The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland.
See More
Previous Close:
$0.4483
Open:
$0.4404
24h Volume:
1.21M
Relative Volume:
1.51
Market Cap:
$4.20M
Revenue:
-
Net Income/Loss:
$-18.35M
P/E Ratio:
-0.377
EPS:
-1.16
Net Cash Flow:
$-19.20M
1W Performance:
-16.58%
1M Performance:
+5.30%
6M Performance:
-69.84%
1Y Performance:
-68.43%
1-Day Range:
$0.43
$0.4515
1-Week Range:
$0.4067
$0.53
52-Week Range:
$0.3654
$2.64
Theriva Biologics Inc Stock (TOVX) Company Profile
Name
Theriva Biologics Inc
Sector
Industry
Phone
301 417 4364
Address
9605 Medical Center Drive, Suite 270, Rockville
Compare TOVX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TOVX
Theriva Biologics Inc
|
0.4373 | 4.30M | 0 | -18.35M | -19.20M | -1.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Theriva Biologics Inc Stock (TOVX) Latest News
What institutional flow reveals about Theriva Biologics Inc.Earnings Recap Summary & High Return Stock Watch Alerts - newser.com
What indicators show strength in Theriva Biologics Inc.2025 Market WrapUp & Free Real-Time Market Sentiment Alerts - newser.com
Why retail investors favor Theriva Biologics Inc. stockWeekly Trend Report & Daily Chart Pattern Signals - newser.com
What technical signals suggest for Theriva Biologics Inc. stockTrade Ideas & Long-Term Investment Growth Plans - newser.com
Theriva Biologics Presents Promising Phase 2b Trial Data - TipRanks
Real time breakdown of Theriva Biologics Inc. stock performanceJuly 2025 Review & Expert Approved Momentum Ideas - newser.com
Theriva Biologics, Inc. Announces Presentation of VIRAGE Phase 2b Trial Data - TradingView
How to use Fibonacci retracement on Theriva Biologics Inc.Portfolio Risk Report & Weekly Consistent Profit Watchlists - newser.com
How analysts rate Theriva Biologics Inc. stock todayTrade Exit Summary & Low Risk Profit Maximizing Plans - newser.com
What momentum shifts mean for Theriva Biologics Inc.Quarterly Trade Report & Growth Focused Entry Reports - newser.com
Is Theriva Biologics Inc. stock entering bullish territory2025 Technical Overview & Fast Momentum Entry Tips - newser.com
Is Theriva Biologics Inc. stock attractive post correctionQuarterly Market Review & Technical Confirmation Alerts - newser.com
Is Theriva Biologics Inc. stock attractive for long term wealth buildingEarnings Overview Summary & Low Volatility Stock Suggestions - newser.com
Theriva™ Biologics Announces Upcoming Presentations at Medical Meetings - GlobeNewswire
VCN-01 expanded mPDAC data: Theriva Biologics to present at ESMO 2025; SYN-004 safety/PK at IDWeek - Stock Titan
How interest rate cuts could boost Theriva Biologics Inc. stockJuly 2025 Retail & Capital Efficiency Focused Ideas - newser.com
Theriva Biologics Inc. stock chart pattern explainedOil Prices & Weekly Watchlist for Consistent Profits - newser.com
Is this a good reentry point in Theriva Biologics Inc.2025 Sector Review & Stock Portfolio Risk Control - newser.com
Multi factor analysis applied to Theriva Biologics Inc.Trade Risk Assessment & AI Based Trade Execution Alerts - newser.com
Will breakout in Theriva Biologics Inc. lead to full recoveryMarket Growth Report & Low Volatility Stock Recommendations - newser.com
Theriva Biologics Presents Promising VCN-12 Preclinical Data - MSN
What downside risks could hit Theriva Biologics Inc. stock2025 Short Interest & Accurate Buy Signal Notifications - newser.com
What analysts say about Theriva Biologics Inc SFY0 stockCash Flow Trends & Diversify Intelligently to Avoid Big Hits - earlytimes.in
Theriva™ Biologics Announces Presentation Describing Next Generation Oncolytic Adenovirus VCN-12 at the 32nd Annual Congress of the European Society of Gene & Cell Therapy (ESGCT) - Sahm
Theriva Biologics Unveils VCN-12 Preclinical Data - TipRanks
Theriva™ Biologics Announces Presentation Describing Next - GlobeNewswire
VCN-12 Preclinical Data: Theriva Presents Novel Mechanism; VCN-01 Intracranial Feasibility at ESGCT - Stock Titan
How Theriva Biologics Inc. stock performs after earnings2025 Winners & Losers & Weekly Consistent Profit Watchlists - newser.com
Visual analytics tools that track Theriva Biologics Inc. performance2025 Major Catalysts & Accurate Technical Buy Alerts - newser.com
Should you hold or exit Theriva Biologics Inc. now2025 Market Trends & Community Consensus Stock Picks - newser.com
What drives Theriva Biologics Inc stock pricePrice Volatility Patterns & Free Get High Potential Alerts - earlytimes.in
Is Theriva Biologics Inc. (SFY0) stock a defensive play amid uncertainty2025 Market Outlook & Smart Money Movement Tracker - newser.com
Is it time to cut losses on Theriva Biologics Inc.July 2025 Pullbacks & AI Forecasted Entry and Exit Points - newser.com
Rumble, XCel Brands And 3 Stocks To Watch Heading Into Friday - Benzinga
Will Theriva Biologics Inc. stock remain on Wall Street radarIPO Watch & Stepwise Entry and Exit Trade Signals - newser.com
Theriva Biologics Inc Stock (TOVX) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.15%
1.45%
Cap:
|
Volume (24h):